ReviewNeurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics2007
Interferon-beta treatment for multiple sclerosis.
Review in Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- Oral delivery of oligomeric procyanidins in Apple Poly® enhances type I IFN responses in vivo.Journal of leukocyte biology · 2014Trial
- Therapeutic Approaches for HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis: Current and Emerging Strategies.Pathogens (Basel, Switzerland) · 2026Review
- Atypical adverse events in a real-world study of long-term immunomodulation for multiple sclerosis and neuromyelitis optica spectrum disorder.Therapeutic advances in neurological disorders · 2025Article
- Long-Term Disability Outcomes in Relapsing-Remitting Multiple Sclerosis Patients: Impact of Clinical and Demographic Factors on Disease Progression.Journal of clinical medicine · 2024Article
- Short and Medium Chain Fatty Acids in a Cohort of Naïve Multiple Sclerosis Patients: Pre- and Post-Interferon Beta Treatment Assessment.Biologics : targets & therapy · 2024Article
- Five-year efficacy outcomes of ocrelizumab in relapsing multiple sclerosis: A propensity-matched comparison of the OPERA studies with other disease-modifying therapies in real-world lines of treatments.Journal of central nervous system disease · 2024Article
- Consecutive Injection of High-Dose Lipopolysaccharide Modulates Microglia Polarization via TREM2 to Alter Status of Septic Mice.Brain sciences · 2023Article
- Therapeutic and Prophylactic Use of Oral, Low-Dose IFNs in Species of Veterinary Interest: Back to the Future.Veterinary sciences · 2021Review
- Transcription cofactor GRIP1 differentially affects myeloid cell-driven neuroinflammation and response to IFN-β therapy.The Journal of experimental medicine · 2021Article
- Innate Signaling in the CNS Prevents Demyelination in a Focal EAE Model.Frontiers in neuroscience · 2021Article
- Review
- Review
- The hematopoietic regulator, ELF-1, enhances the transcriptional response to Interferon-β of the OAS1 anti-viral gene.Scientific reports · 2015Article
- Interferon-Beta Therapy of Multiple Sclerosis Patients Improves the Responsiveness of T Cells for Immune Suppression by Regulatory T Cells.International journal of molecular sciences · 2015Article
- High-throughput quantitative real-time RT-PCR assay for determining expression profiles of types I and III interferon subtypes.Journal of visualized experiments : JoVE · 2015Article
- Knowledge and attitude assessment of Iranian multiple sclerosis patients receiving interferon beta.Iranian journal of neurology · 2014Article
- Antibodies to interferon beta in patients with multiple sclerosis receiving CinnoVex, rebif, and betaferon.Journal of Korean medical science · 2013Article
- Rapid exacerbation of multiple sclerosis following the initiation of interferon-β: report of nine cases.Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2011Article
- Conformation and dynamics of biopharmaceuticals: transition of mass spectrometry-based tools from academe to industry.Journal of the American Society for Mass Spectrometry · 2010Article
- Current status and challenges of cytokine pharmacology.British journal of pharmacology · 2009Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiple sclerosis (MS) is the leading nontraumatic cause of neurologic disability in young adults. Interferon-beta, approved for use in 1993, was the first treatment to modify the course and prognosis of the disease and remains a mainstay of MS treatment. Numerous large-scale clinical trials in early, active patient populations have established the clinical efficacy of interferon-beta in reducing relapses and delaying disability progression. Although its mechanism of action remains incompletely understood, a reduction in active lesions seen on magnetic resonance imaging implies primary anti-inflammatory properties, a mechanism supported by basic immunologic research. Variation in individual patient responsiveness to interferon-beta may be due to disease variability or differential induction of interferon-stimulated genes. The magnitude of the therapeutic effect appears to be similar among products, but the optimal dose, route, and frequency of administration of the drug remain uncertain.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.